JP2021534227A5 - - Google Patents

Info

Publication number
JP2021534227A5
JP2021534227A5 JP2021529249A JP2021529249A JP2021534227A5 JP 2021534227 A5 JP2021534227 A5 JP 2021534227A5 JP 2021529249 A JP2021529249 A JP 2021529249A JP 2021529249 A JP2021529249 A JP 2021529249A JP 2021534227 A5 JP2021534227 A5 JP 2021534227A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
compound described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021529249A
Other languages
English (en)
Japanese (ja)
Other versions
JP7319369B2 (ja
JP2021534227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044814 external-priority patent/WO2020086136A2/en
Publication of JP2021534227A publication Critical patent/JP2021534227A/ja
Publication of JP2021534227A5 publication Critical patent/JP2021534227A5/ja
Application granted granted Critical
Publication of JP7319369B2 publication Critical patent/JP7319369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529249A 2018-08-03 2019-08-02 ヘテロ芳香族nmda受容体モジュレーターおよびその使用 Active JP7319369B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
US62/714,100 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (3)

Publication Number Publication Date
JP2021534227A JP2021534227A (ja) 2021-12-09
JP2021534227A5 true JP2021534227A5 (enExample) 2022-08-10
JP7319369B2 JP7319369B2 (ja) 2023-08-01

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529249A Active JP7319369B2 (ja) 2018-08-03 2019-08-02 ヘテロ芳香族nmda受容体モジュレーターおよびその使用

Country Status (37)

Country Link
US (5) US10584131B2 (enExample)
EP (2) EP3830092B1 (enExample)
JP (1) JP7319369B2 (enExample)
KR (1) KR102797968B1 (enExample)
CN (1) CN112513047B (enExample)
AR (1) AR115905A1 (enExample)
AU (1) AU2019368147B2 (enExample)
BR (1) BR112021001967A2 (enExample)
CA (1) CA3108519A1 (enExample)
CL (1) CL2021000294A1 (enExample)
CO (1) CO2021002898A2 (enExample)
CR (1) CR20210125A (enExample)
CU (1) CU24647B1 (enExample)
CY (1) CY1126144T1 (enExample)
DK (1) DK3830092T3 (enExample)
DO (1) DOP2021000025A (enExample)
EA (1) EA202190431A1 (enExample)
EC (1) ECSP21014902A (enExample)
ES (2) ES2951872T3 (enExample)
FI (1) FI3830092T3 (enExample)
HR (1) HRP20230774T1 (enExample)
HU (1) HUE062566T2 (enExample)
IL (1) IL280474B2 (enExample)
JO (1) JOP20210020A1 (enExample)
LT (1) LT3830092T (enExample)
MA (1) MA53351B1 (enExample)
MX (1) MX2021001367A (enExample)
PE (1) PE20210948A1 (enExample)
PH (1) PH12021550242A1 (enExample)
PL (1) PL3830092T3 (enExample)
PT (1) PT3830092T (enExample)
RS (1) RS64359B1 (enExample)
SG (1) SG11202101125VA (enExample)
SI (1) SI3830092T1 (enExample)
TW (1) TWI833783B (enExample)
WO (1) WO2020086136A2 (enExample)
ZA (1) ZA202101273B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
NZ575426A (en) 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
EP2066640B1 (en) 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP5675341B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102112475A (zh) 2008-05-29 2011-06-29 西特里斯药业公司 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
BRPI0914006A2 (pt) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazóis e análogos relacionados como moduladores de sirtuína
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CN102666540A (zh) 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Nr2a之n-芳基甲基磺醯胺負向調節劑
PT3055315T (pt) 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
WO2016081649A1 (en) * 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
KR20180102052A (ko) 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações

Similar Documents

Publication Publication Date Title
RS55353B1 (sr) Tenofovir alafenamid hemifumarat
JP2023518830A5 (enExample)
JP2020183410A5 (enExample)
JP2012521994A5 (enExample)
JP2018115191A5 (enExample)
JP2019507160A5 (enExample)
JP2017531038A5 (enExample)
JP2022533912A5 (enExample)
JP2019507781A5 (enExample)
JP2017524025A5 (enExample)
JP2015512951A5 (enExample)
JP2013516473A5 (enExample)
JP2015500223A5 (enExample)
JP2017533968A5 (enExample)
CA2386297A1 (en) Bicyclic amino acids as pharmaceutical agents
JP2022515293A5 (enExample)
JP2022519744A5 (enExample)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2016512517A (ja) ロイコトリエンa4加水分解酵素を阻害する方法
JP2016537338A5 (enExample)
JP2019527724A5 (enExample)
JP2016537432A5 (enExample)
JP2024542610A5 (enExample)
JP2012532125A5 (enExample)
US20210198218A1 (en) Compounds for therapeutic use